Download Approach to Pulmonary Problems of Immunosuppressed Patients

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Approach to Pulmonary Problems
of Immunosuppressed Patients
Dr.Özlem Özdemir Kumbasar
1



Pulmonary complications are frequent
and life-threatining problems in
immunocompromised patients.
Early diagnosis for optimal treatment is
very important.
Empirical therapy should be started as
soon as possible for most of the
patients.
2

The number of immunosuppressed patients
has increased recently:







Neutropenia following cancer chemotherapy
Hematological malignancy
Solid organ transplantation
Hematopoietic stem cell transplantation
Immunosuppressive treatments for auto-immune
diseases
HIV infection
…………
3


Rapid diagnosis is necessary because of
high mortality.
To obtain an etiological diagnosis is
usually difficult and sometimes requires
invasive diagnostic methods.
4

To obtain an etiological diagnosis is
difficult. Because:




Clinical findings may be silent
Clinical picture is nonspecific
Infectious and non-infectious diseases can
be seen together
More than one infectious agent may be
responsible for the pulmonary problem
5

Sometimes invasive diagnostic methods
are necessary. But, usually these
procedures are difficult for these
patients:



General condition of the patient?
Respiratory failure?
Thrombocytopenia?
6
Approach to Pulmonary Complications in
an Immunosupressed Patient


Clinical evaluation
Radiologial findings
Empirical treatment

Diagnostic tests
7
Clinical Evaluation

Type of imunosuppression



Neutropenia
Humoral immunodeficiency
Cellular immunodeficiency
8
Neutropenia

Gram-negative rods

S.aureus



Coagulase-negative staphylococci
Viridans streptococci
Aspergillus
9
Neutropenia

Long lasting profound neutropenia:






Fungi
Multiresistent gram negative rods (P.aeruginosa,
S.maltophilia) and other bacteria
P.jiroveci
Viruses
……………
Noninfectious diseases





Alveolar bleeding
COP
Lesions due to chemo- or radiotherapy
Malign infiltration
……………
10
Humoral immunosuppresion

Pneumococcus

H.influenzae
11
Cellular immunosuppression







M.tuberculosis
P.jiroveci
Legionella
Nocardia
Nontuberculous mycobacteria
Fungi
Viruses
12
Clinical evaluation

Medical history





Type, intensity and duration of
immunosuppression
Previous treatments
Prophylaxis
CAP? HAP?
Condition of the hospital
13
Clinical evaluation

Timing of the complication


HSCT
SOT
14
Timing

HSCT

Preengraftment phase (0-30days)



Early postengraftment phase (30-100days)



Bacteria, Candida, Aspergillus
DAH, IPS, engraftment syndrome
CMV, PCP, Aspergillus
IPS
Late posttransplant phase (>100days)




CMV, VZV, community acquired viruses, pneumococcus,
H.influenzae, tuberculosis
BOOP
PTLD
BO
15
Timing

SOT

0-1 month:



1-6 months:





HAP
Fungi
Aspergillus
PCP
CMV, other viruses
Nocardia
>6 months:


CAP
Tuberculosis
16
Clinical evaluation

Clinical behavior of the complication

Acute





Bacteria
Viruses
PCP (nonHIV patients)
Pulmonary edema, DAH, PTE….
Subacute/chronic

Aspergillus

CMV

Nocardia

Tuberculosis
17
Symptoms

Symptoms are usually nonspecific




Cough
Fever
Dyspnea
Skin lesions-bacteria, fungi




Nodules-Aspergillus, Nocardia
Invasive sinusitis-mucor, Aspergillus, Fusarium
Corioretinitis-CMV
Brain abscess-Nocardia, Aspergillus,
Pseudomonas, Toxoplasma
18
Radiological findings


To evaluate radiological clues is vey
important for planning rapid and
optimal empirical therapy
The main radiological patterns:



Focal infiltrate-consolidation
Nodular infiltrates
Diffuse interstitial infiltrates
19

Additional radiological findings





Cavitation
Pleural effusion
Atelectasis
Lymphadenopathy
Pneumothorax
20

Acute/focal infiltrates




Bacteria
Aspergillus
Legionella
Subacute-chronic/focal infiltrates



Aspergillus
Nocardia
M.tuberculosis, MAI
21


Acute/nodular(+cavity) infiltrates

Bacterial lung abscess

Legionella
Subacute-chronic/nodular (+cavity)




Tuberculosis
Nocardia
Aspergillus
Cryptococcus
22


Acute/diffuse interstitial infiltrates

CMV

P.jiroveci
Subacute-chronic/diffuse intertitial

CMV

P.jiroveci


RSV
Miliary tuberculosis
23
24
25
26
27
28
Noninfectious disorders

Diffuse










Pulmonary edema
BOOP-COP
NSIP
LIP
Drug induced pneumonitis
Lymphangitic metastasis
DAH
IPS
Radiation toxicity
PAP
29
Noninfectious disorders

Nodular + cavity




Malignancy
Septic embolism
Kaposi sarcoma
Posttransplant lymphoprolipherative
disorder
30
Noninfectious disorders

Focal







BOOP-COP
Radiation toxicity
Pulmonary embolism and infarctus
Phantom tumor
Primary/metastatic tumor
Atelectasis
Kaposi
31
32


Computed tomography detects
pulmonary iniltrates earlier than chest
x-ray.
CT gives valuable information about
characteristics of the pulmonary
infiltrate.

The diagnosis of pulmonary aspergillosis,
PCP, CMV pneumonia could be suspected
from the typical CT findings.
33

CT findings of invasive pulmonary
aspergillosis






Single or multiple nodules
Mass like appearence
Consolidation-especially pleural based, wedge
shaped
Halo sign
Cavitation
Air-crescent sign
34
35
36
37
38

Similar BT findings may be seen in
other invasive fungal infections,
nocardiosis.
39

Halo sign

IPA->%60 (early finding)
Pulmonary zygomycosis-%25
40

Reverse halo sign


Central ground-glass opacity, surrounding
consolidation
Reverse halo sign may be seen in COP
41
42

189 patients with fungal pneumonia


Reverse halo sign in 8 patients (7zygomycosis; 1 aspergillosis)
Reverse halo sign was detected in 19% of
patients with zygomycosis and <1% of
aspergillosis.
43

PCP-CT findings:



Ground glass opacities
Interlobular septal thickening
Cystic lesions
44
PCP
45
OP
46
47
48
49
50
51
52